Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease. This evidence concerns the gene MTOR and metabolic dysfunction-associated steatotic liver disease.